They don't lose their patent for certain indications and this was known for years that it was coming as they have been in and out of court for a while trying to defend the patent. Only one biosimilar hits the market now. More can be released in July. Probably won't see any major change until start of quarter 3
Edit to also add that they have had recent success with expanded indication approvals for skyrizi and rinvoq to replace humira in the market share and they are actually doing really well with prescribers. Abbvie has some top notch drug reps and a really great bridge to coverage programs that have expanded access to these other drugs drastically.
Taiyonay t1_j69sk23 wrote
Reply to comment by Trash_Panda-1 in Abbvie to lose most lucrative patent protection one week before Q4 earnings call. by [deleted]
They don't lose their patent for certain indications and this was known for years that it was coming as they have been in and out of court for a while trying to defend the patent. Only one biosimilar hits the market now. More can be released in July. Probably won't see any major change until start of quarter 3
Edit to also add that they have had recent success with expanded indication approvals for skyrizi and rinvoq to replace humira in the market share and they are actually doing really well with prescribers. Abbvie has some top notch drug reps and a really great bridge to coverage programs that have expanded access to these other drugs drastically.